Century Therapeutics, Inc. Common Stock

IPSCNASDAQUSD
2.19 USD
0.06 (2.82%)AT CLOSE (11:59 AM EDT)
2.18
0.02 (0.96%)
POST MARKET (AS OF 04:59 PM EDT)
Post Market
AS OF 04:59 PM EDT
2.18
0.02 (0.96%)
🟢Market: OPEN
Open?$2.13
High?$2.30
Low?$2.13
Prev. Close?$2.13
Volume?1.5M
Avg. Volume?1.5M
VWAP?$2.23
Rel. Volume?1.04x
Bid / Ask
Bid?$1.90 × 100
Ask?$2.51 × 100
Spread?$0.61
Midpoint?$2.21
Valuation & Ratios
Market Cap?382.8M
Shares Out?179.7M
Float?45.2M
Float %?51.8%
P/E Ratio?N/A
P/B Ratio?2.41
EPS?-$0.05
Dividend?0.00%
Ex-Dividend?N/A
Technical Outlook
Loading...
Fundamental Outlook
Loading...
Short Interest
Loading...
Financial Health
Current Ratio?5.97Strong
Quick Ratio?5.97Strong
Cash Ratio?3.06Strong
Debt/Equity?0.00Low
ValuationFAIRLY VALUED
Score
75/100
P/E?
N/A
P/B?
2.41CHEAP
P/S?
3.51FAIR
P/FCF?
N/A
EV/EBITDA?
123.4HIGH
EV/Sales?
2.94CHEAP
Returns & Efficiency
ROE?
-6.0%WEAK
ROA?
-4.3%WEAK
Cash Flow & Enterprise
FCF?$-104724000
Enterprise Value?$321.0M
Related Companies
Loading...
News
Profile
Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.
Employees
78
Market Cap
382.8M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed
2021-06-18
Address
25 N 38TH STREET, 11TH FLOOR
PHILADELPHIA, PA 19104
Phone: 215-981-4000